Hyperhomocysteinemia and the endocrine system: Implications for atherosclerosis and thrombosis

Endocrine Reviews

Volumn 20, Issue 5, 1999, Pages 738-759

  Fonseca, V ^a   Guba, S C ^a   Fink, L M ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PYRIDOXINE;

AMINO ACID METABOLISM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; ENDOCRINE SYSTEM; HORMONE METABOLISM; HUMAN; HYPERHOMOCYSTEINEMIA; NOMENCLATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR DISEASE;

EID: 0033304841     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.20.5.0381     Document Type: Review

References (204)

1. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
2. Nutritional ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid
3. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
4. 6, pyridoxal phosphate, and folate
5. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis
6. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
7. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
8. Hyperhomocysteinemia: An independent risk factor for vascular disease
9. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
10. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis
11. The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease
12. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study
13. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
14. Homocystinuria. Clinical and pathological review of ten cases
15. Homocystinuria. Studies of 20 families with 38 affected members
16. Vascular pathology of homocysteinemia. Implications for the pathogenesis of arteriosclerosis
17. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease
18. 223Val MTHFR) in patients with inherited thrombophilic coagulation defects
19. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians
20. Disorders of transsulfuration
21. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine
22. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease
23. Allosteric inhibition of methylenetetra-hydrofolate reductase by adenosylmethionine
24. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine
25. Hyperhomocysteinemia - An emerging and important risk factor for thromboembolic and cardiovascular disease
26. Total homocysteine in plasma or serum: Methods in clinical applications
27. Homocysteine export from erythrocytes and its implication for plasma sampling
28. Homocysteine and other thiols in plasma and urine: Automated determination in sample stability
29. Homocyst(e)inemia in daily practice: Levels in coronary heart disease
30. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott Imx® Analyser
31. Enyzme conversion immunoassay for determining total homocysteine in plasma or serum
32. Short-term and long-term variability of plasma homocysteine measurement
33. Disordered methionine/homocysteine metabolismin premature vascular disease. Its occurence, cofactor therapy, and enzymology
34. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: Initial results from the NHLBI Family Heart Study
35. Determinants of hyperhomocysteinemia: A matter of nature and nurture
36. Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits
37. Effects of age, lipoproteins, and hemostatic parameters on the role of homocysteinemia as a cardiovascular risk factor in men
38. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
39. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum colbalamin
40. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study
41. Role of blood pressure, uric acid, and hemorrheological parameters on plasma homocyst(e)ine concentration
42. Plasma homocysteine in the acute and convalescent phases after stroke
43. Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid
44. Inherited disorders of cobalamin transport and metabolism
45. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria
46. 833C/68 bp Insertion' in cystathionine β-synthase gene in Northern and Southern Italian populations. Letter to the Editor
47. Human cystathionine beta-synthase cDNA: Sequence, alternate splicing and expression in cultured cells
48. Two novel missense mutations in the cystathionine β-synthase gene in homocystinuric patients
49. Amplification refractory mutation system to identify mutations in cystathionine β-synthase deficiency
50. 919A mutations of the cystathionine β-synthase gene by single-strand conformational polymorphism
51. The molecular basis of homocystinuria due to cystathionine β-synthase deficiency in Italian families, and report of four novel mutations
52. High prevalence of a mutation in the cystathionine beta-synthase gene
53. Homocysteine response to methionine challenge in four obligate heterozygotes for homocystinuria and relationship with cystathionine β-synthase mutations
54. Defective cystathionine β-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient
55. Human methylenetetrahydrofolate reductase isolation of cDNA mapping and mutation identification
56. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease
57. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease
58. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
59. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes
60. The relationship between MTHFR genotype, serum homocysteine and folate levels
61. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
62. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease
63. Human methionine synthase. CDNA cloning, gene localization, and expression
64. Sequence analysis of the coding region of human methionine synthase: Relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease
65. Vitamin B12-responsive neonatal megaloblastic anemia and homocystinuria with associated reduced methionine synthase activity
66. Functional methionine synthase deficiency due to cblG disorder: A report of two patients and a review
67. Folate-responsive homocystinuria and megaloblastic anaemia in a female patients with functional methionine synthase deficiency (cbl E disease)
68. Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC)
69. Defects in human methionine synthase in cblG patients
70. Plasma folate adequacy as determined by homocysteine level
71. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women
72. Vitamin intake: A possible determinant of plasma homocyst(e)ine among middle-aged adults
73. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
74. The responsiveness of plasma homocysteine to small increases in dietary folic acid: A primary care study
75. Folate intake in Europe: Recommended, actual and desired intake
76. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
77. Vitamin B-6 deficiency vs. folate deficiency: Comparison of responses to methionine loading in rats
78. Total homocysteine in fasting plasma is not a good indicator of B6 deficiency
79. The effect of a subnormal vitamin B-6 status on homocysteine metabolism
80. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
81. Human homocysteine catabolism: Three major pathways and their relevance to development of arterial occlusive disease
82. Total homocyst(e)ine in plasma and amniotic fluid of pregnant women
83. Decreased serum homocysteine in pregnancy
84. Methionine metabolism in mammals. Effect of age, diet, and hormones on three enzymes of the pathway in rat tissues
85. Plasma homocysteine and menopausal status
86. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status
87. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women
88. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females
89. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen
90. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine
91. The effect of supraphysiologic doses of testosterone on fasting total homocysteine levels in normal men
92. Homocysteine and cysteine: Determinants of plasma levels in middle-aged and elderly subjects
93. Effects of sex steroids on plasma total homocysteine in male-to-female and female-to-male trans-sexuals
94. Cortisol and estradiol: Nongenetic factors for hyperhomocyst(e)inemia
95. Homocysteine and vascular disease
96. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients
97. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
98. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease
99. Plasma homocysteine and its relationship to cardiovascular risk factors in a Japanese population
100. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study
101. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: Effect of parenteral methylcobalamin treatment
102. Oxidative stress and diabetic vascular complications
103. Homocysteine and atherothrombosis
104. Oxidative stress in diabetic macrovascular disease: Does homocysteine play a role?
105. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus
106. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study
107. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM
108. Elevated plasma homocysteine and diabetic vascular disease
109. Hyperhomocysteinemia and microalbuminuria in diabetes
110. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease?
111. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients
112. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus
113. Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study
114. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria
115. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
116. Net uptake of plasma homocysteine by the rat kidney in vivo
117. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
118. Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients
119. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
120. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects
121. Banting lecture. Role of insulin resistance in human disease
122. 35 methionine
123. Effect of endogenous insulin on human amino acid metabolism
124. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia
125. Effects of insulin resistance on enzymes of homocysteine metabolism in the rat
126. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?
127. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease
128. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients
129. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia
130. Elevated high-density lipoprotein cholesterol, not protective in the presence of homocysteinemia
131. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
132. The oxidant stress of hyperhomocyst(e)inemia
133. Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein
134. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia
135. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
136. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease
137. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease
138. Plasma homocysteine levels and mortality in patients with coronary artery disease
139. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis
140. Association between plasma homocysteine and extracranial carotid arterial disease in older persons
141. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study
142. Correlation between plasma homocyst(e)ine and aortic atherosclerosis
143. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam Study
144. Relationship of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
145. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery
146. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12, and folate
147. Down's syndrome: An atheroma-free model?
148. Cloning and screening with nanogram amounts of immunopurified mRNAs: cDNA cloning and chromosomal mapping of cystathionine beta-synthase and the beta subunit of propionyl-CoA carboxylase
149. Is absence of atheroma in Down syndrome due to decreased homocysteine levels?
150. Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionmine β-synthase
151. Effective homocysteine metabolism may protect South African blacks against coronary heart disease
152. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: Findings in two populations at contrasting risk for coronary heart disease
153. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect?
154. Relationship of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians
155. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis
156. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism
157. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats
158. Activation of Hageman factor by L-homocystine
159. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells
160. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine
161. Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis
162. Diet responsive proconvertin (factor VII) deficiency in homocystinuria
163. Antithrombin activity in homocystinuria
164. Homocystinuria: Clinical and pathologic review, with emphasis on thrombotic features, including pulmonary artery thrombosis
165. Coagulation factors and markers of activation of coagulation in homocystinuria (HOCY): A study in two siblings
166. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells
167. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans
168. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents
169. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
170. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation on pancreatic vascular bed in rats
171. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
172. Homocysteine catabolism: Levels of 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease
173. The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells (HUVECs)
174. Endothelial cell dysfunction in homocystinuria
175. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels
176. Homocysteine mediated endothelial cell toxicity and its amelioration
177. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine
178. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia
179. Homocysteine metabolism and the oxidative modification of proteins and lipids
180. Endothelial marker proteins in hyperhomocysteinemia
181. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease
182. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters
183. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells
184. Inhibition of cyclooxygenase activity in human endothelial cells by homocysteine
185. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
186. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations
187. Homocysteine increases cyclin-dependent kinase in aortic rat tissue
188. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells
189. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine
190. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: A possible role for hydrogen peroxide
191. Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid
192. Treatment of mild hyperhomocysteinemia in vascular disease patients
193. Blood coagulation changes in homocystinuria: Effects of pyridoxine and other specific therapy
194. Pyridoxine therapy in homocystinuria
195. Affinity of cystathionine β-synthase for pyridoxal 5'-phosphate in cultured cells. A mechanism for pyridoxine-responsive homocystinuria
196. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment
197. Vitamin requirements for the treatment of hyperhomocysteinemia in humans
198. Vitamin status and hyperhomocysteinemia in a healthy population
199. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations
200. Treatment of mild hyperhomocysteinemia
201. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia
202. Betaine for homocystinuria
203. The use of betaine for the treatment of homocystinuria
204. Homocystinuia - The effect of betaine in the treatment of patients not responsive to pyridoxine